| P2093 | author name string | David W Speicher | |
| | Hsin-Yao Tang | |
| | Kurt T Barnhart | |
| | Lynn A Beer | |
| P2860 | cites work | Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS | Q24680943 |
| | The human plasma proteome: history, character, and diagnostic prospects | Q28218148 |
| | Peroxiredoxin 6, a 1-Cys peroxiredoxin, functions in antioxidant defense and lung phospholipid metabolism | Q28250381 |
| | Cathepsin D expression levels in nongynecological solid tumors: clinical and therapeutic implications | Q28264029 |
| | Cathepsin D--many functions of one aspartic protease | Q28275626 |
| | Quantitative analysis of the intra- and inter-individual variability of the normal urinary proteome | Q28299737 |
| | Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry | Q33370510 |
| | Combination of improved (18)O incorporation and multiple reaction monitoring: a universal strategy for absolute quantitative verification of serum candidate biomarkers of liver cancer | Q33564849 |
| | Advances in Proximal Fluid Proteomics for Disease Biomarker Discovery | Q33731966 |
| | Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma | Q33794491 |
| | Revealing novel telomere proteins using in vivo cross-linking, tandem affinity purification, and label-free quantitative LC-FTICR-MS | Q33883012 |
| | Secretome proteomics for discovery of cancer biomarkers | Q34023121 |
| | Options and considerations when selecting a quantitative proteomics strategy | Q34125509 |
| | Biomarkers: mining the biofluid proteome | Q34389937 |
| | Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins | Q34473545 |
| | Systematic discovery of ectopic pregnancy serum biomarkers using 3-D protein profiling coupled with label-free quantitation | Q34625328 |
| | A systems biology analysis of metastatic melanoma using in-depth three-dimensional protein profiling | Q34762291 |
| | A disintegrin and metalloprotease protein-12 as a novel marker for the diagnosis of ectopic pregnancy | Q34771744 |
| | The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum | Q35010986 |
| | In-depth analysis of a plasma or serum proteome using a 4D protein profiling method | Q35169891 |
| | Candidate-based proteomics in the search for biomarkers of cardiovascular disease | Q35990040 |
| | Protein biomarker discovery and validation: the long and uncertain path to clinical utility | Q36561644 |
| | Higher dimensional (Hi-D) separation strategies dramatically improve the potential for cancer biomarker detection in serum and plasma | Q36671188 |
| | Comparative evaluation of current peptide production platforms used in absolute quantification in proteomics | Q36685018 |
| | Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution | Q36731097 |
| | Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. | Q37379631 |
| | Advances in proteomic prostate cancer biomarker discovery | Q37732602 |
| | Proteomics of colorectal cancer: overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers. | Q37769958 |
| | On the development of plasma protein biomarkers | Q37818127 |
| | Phospholipase A2 activity of peroxiredoxin 6 promotes invasion and metastasis of lung cancer cells | Q39720803 |
| | Peroxiredoxin 6 promotes lung cancer cell invasion by inducing urokinase-type plasminogen activator via p38 kinase, phosphoinositide 3-kinase, and Akt. | Q39770956 |
| | Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry | Q39860915 |
| | Targeted label-free quantitative analysis of secretory proteins from adipocytes in response to oxidative stress | Q42828571 |
| | Molecular forms of β-hexosaminidase and cathepsin D in serum and urine of healthy subjects and patients with elevated activity of lysosomal enzymes | Q42864708 |
| | Application of an end-to-end biomarker discovery platform to identify target engagement markers in cerebrospinal fluid by high resolution differential mass spectrometry | Q43185959 |
| | Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-Ms/MS using protein cleavage and isotope dilution mass spectrometry | Q44978185 |
| | Multiple reaction monitoring of mTRAQ-labeled peptides enables absolute quantification of endogenous levels of a potential cancer marker in cancerous and normal endometrial tissues | Q46481136 |
| | Cathepsin D is a potential serum marker for poor prognosis in glioma patients | Q48852906 |
| | Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. | Q51907503 |
| | Computational prediction of proteotypic peptides for quantitative proteomics. | Q51925913 |
| | Multiplexed absolute quantification for proteomics using concatenated signature peptides encoded by QconCAT genes | Q58023456 |
| | A Synthetic Protein Approach toward Accurate Mass Spectrometric Quantification of Component Stoichiometry of Multiprotein Complexes | Q58416438 |
| | Isotope-labeled Protein Standards | Q58441935 |
| | Isotope dilution--mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I | Q64134355 |
| | Absolute quantification of the G protein-coupled receptor rhodopsin by LC/MS/MS using proteolysis product peptides and synthetic peptide standards | Q72995434 |
| | Increased cathepsin D level in the serum of patients with metastatic breast carcinoma detected with a specific pro-cathepsin D immunoassay | Q73404718 |
| | Cathepsin D serum levels are not a valid serum marker in renal cell carcinoma | Q80602767 |
| | High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites | Q80651821 |
| | How specific is my SRM?: The issue of precursor and product ion redundancy | Q83409275 |
| P433 | issue | 9 | |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 4005-4017 | |
| P577 | publication date | 2011-07-26 | |
| P1433 | published in | Journal of Proteome Research | Q3186939 |
| P1476 | title | Rapid verification of candidate serological biomarkers using gel-based, label-free multiple reaction monitoring | |
| P478 | volume | 10 | |